Biologics World Taiwan 2027 (Outside Asian Biopharma)

Upstream yields look great on the slide. Then someone asks how they'll hold up at commercial scale, whether the assay is ready for the regulator, and when the first patient gets dosed. Suddenly the coffee break is the most useful 15 minutes of your week.

Biologics World Taiwan has been setting up that kind of conversation in Taipei for 13 years. The 2027 edition again brings the three parts of the biologics pipeline into one room.

Three tracks, one pipeline

• Manufacturing: the part where a promising molecule has to survive scale-up, quality checks and the realities of production.

• R&D: the discovery and development work that decides which candidates are worth all that effort.

• Clinical trials: the step where the science meets patients and the data has to hold up.

These teams often work in separate silos. Here, process engineers, research scientists and clinical leads get to argue about the same molecule face to face. It's more productive than an email chain, and the coffee is better.

Who'll get the most out of it

If your job touches biologics anywhere from bench to bedside, you're in the right place. That includes scaling a process, building a pipeline and running studies. And if you've ever wondered why your CMC timeline and your clinical timeline never seem to agree, you'll find people here who have the same headache.

Working in biologics? Save your spot for Biologics World Taiwan 2027.